Aska Of Japan To Start Phase II Europe Trials For IBD Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Aska Pharmaceutical plans to begin European Phase II trials of its AKP-001 compound for treating inflammatory bowel disease in the next fiscal year. Aska also is developing the drug for treating Crohn's disease. If the drug wins regulatory approval, Aska, which has no sales force outside of Japan, plans to license development and marketing rights in Europe and the United States. It plans to develop and market the drug in Japan on its own. (Click here for more - a subscription may be required
|
Japan's Aska Pharmaceutical plans to begin European Phase II trials of its AKP-001 compound for treating inflammatory bowel disease in the next fiscal year. Aska also is developing the drug for treating Crohn's disease. If the drug wins regulatory approval, Aska, which has no sales force outside of Japan, plans to license development and marketing rights in Europe and the United States. It plans to develop and market the drug in Japan on its own. (Click here for more - a subscription may be required) "Aska Preps For European Trials Of Inflammatory Bowel Treatment" - Nikkei (Japan) (7/28/08) |